Paper8532003
Octreotide.
Lamberts SW and 3 others. N Engl J Med, 1996. Cited by 955 papers, by iCite.
Cite this record
ConductScience Library. Octreotide. Papers, record 8532003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8532003
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Hormonal | Major topic |
| Gastrointestinal Agents | Major topic |
| Gastrointestinal Diseases | Major topic |
| Neoplasms | Major topic |
| Octreotide | Major topic |
| Somatostatin | Major topic |
| Acromegaly | |
| Adenoma | |
| Carcinoid Tumor | |
| Humans | |
| Pancreatic Diseases | |
| Pituitary Neoplasms | |
| Receptors, Somatostatin |
Source PubMed
Cited by283
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 955 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42556326 | Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets. | Stem Cells Transl Med | 2026 | https://conductscience.org/library/papers/42556326 | PubMed |
| 42472378 | Unexplored Factors in Medication Wastage: Investigating Economic Impact in a Brazilian Teaching Hospital. | J Eval Clin Pract | 2026 | https://conductscience.org/library/papers/42472378 | PubMed |
| 41827131 | Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827131 | PubMed |
| 41575647 | Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer. | Ann Nucl Med | 2026 | https://conductscience.org/library/papers/41575647 | PubMed |
| 41357395 | Dietary interventions vs octreotide for post liver transplantation chylous ascites: A scoping review. | World J Transplant | 2025 | https://conductscience.org/library/papers/41357395 | PubMed |
| 40638034 | Somatostatin receptor expression in multiple hemangiomas. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40638034 | PubMed |
| 40629899 | The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review. | Nutr Clin Pract | 2025 | https://conductscience.org/library/papers/40629899 | PubMed |
| 40579692 | Reduction of polycystic kidney and liver volumes in a patient with tolvaptan-resistant autosomal dominant polycystic kidney disease and acromegaly during lanreotide therapy. | CEN Case Rep | 2025 | https://conductscience.org/library/papers/40579692 | PubMed |
| 40375949 | Case Report: Diazoxide-induced diabetic ketoacidosis in a patient with insulinoma. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/40375949 | PubMed |
| 40345176 | Antiparallel β-Sheet as a Key Motif of Amyloid-β Inhibitor Designed via Topological Peptide Reprogramming. | Angew Chem Int Ed Engl | 2025 | https://conductscience.org/library/papers/40345176 | PubMed |
| 40305228 | Molecular Modelling in Bioactive Peptide Discovery and Characterisation. | Biomolecules | 2025 | https://conductscience.org/library/papers/40305228 | PubMed |
| 39861670 | Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39861670 | PubMed |
| 39757391 | Acromegaly: diagnostic challenges and individualized treatment. | Expert Rev Endocrinol Metab | 2025 | https://conductscience.org/library/papers/39757391 | PubMed |
| 39747850 | Radiopharmaceuticals and their applications in medicine. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39747850 | PubMed |
| 39693037 | [89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors. | EJNMMI Radiopharm Chem | 2024 | https://conductscience.org/library/papers/39693037 | PubMed |
| 39518342 | Histopathological Evaluation of Somatostatin Receptor 2 Expression in Myocarditis-Rationale for the Diagnostic Use of Somatostatin Receptor Imaging. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/39518342 | PubMed |
| 39456236 | Future Perspective: Harnessing the Power of Artificial Intelligence in the Generation of New Peptide Drugs. | Biomolecules | 2024 | https://conductscience.org/library/papers/39456236 | PubMed |
| 38974572 | Characterization of the somatostatin system in tilapia: implications for growth and reproduction. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38974572 | PubMed |
| 38926478 | Structural insights into somatostatin receptor 5 bound with cyclic peptides. | Acta Pharmacol Sin | 2024 | https://conductscience.org/library/papers/38926478 | PubMed |
| 38541987 | Pleural Effusion and Chylothorax in Congenital Diaphragmatic Hernia-Risk Factors, Management and Outcome. | J Clin Med | 2024 | https://conductscience.org/library/papers/38541987 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8532003
GET https://conductscience.org/api/papers/v1/8532003/cited_by?page=2